C12N 2710/16141
Use of virus, viral particle or viral elements as a vector
C12N2710/16141 (Use of virus, viral particle or viral elements as a vector) appears on 105 US grants and 179 published applications in this corpus.
Search patents in C12N- Granted patents
- 105
- Published applications
- 179
- Assignees
- 117
- Inventors
- 314
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 3 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 5 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 1 | 1 |
| 2010 | 3 | 5 |
| 2011 | 1 | 2 |
| 2012 | 0 | 3 |
| 2013 | 0 | 5 |
| 2014 | 1 | 3 |
| 2015 | 7 | 7 |
| 2016 | 4 | 11 |
| 2017 | 4 | 12 |
| 2018 | 5 | 12 |
| 2019 | 7 | 12 |
| 2020 | 8 | 13 |
| 2021 | 10 | 15 |
| 2022 | 5 | 24 |
| 2023 | 15 | 7 |
| 2024 | 3 | 11 |
| 2025 | 11 | 11 |
| 2026 | 4 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16143Viral genome or elements thereof as genetic vectorIndexing code98
- C12N 2710/16142Virus or viral particle as vehicleIndexing code4
- C12N 2710/16145Special targeting system for viral vectorsIndexing code2
- C12N 2710/16144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Mammalian expression vectors30 Jun 2026US 12,668,809 B2Biocon Biologics Limited
- Hepatitis B virus-specific T cell responses14 Apr 2026US 12,599,658 B2Oregon Health & Science University
- Enabling cholesterol catabolism in mammalian cells lacking same10 Feb 2026US 12,545,918 B2University of South Alabama Foundation for Research and Commercialization
- Optimized SUMF1 genes and expression cassettes and their use6 Jan 2026US 12,516,301 B2The University of North Carolina at Chapel Hill
- Gene therapy for Alzheimer's disease16 Dec 2025US 12,497,608 B2The Brigham and Women S Hospital, Inc.
- Stem cell reprogramming with gene-enhanced stem cells23 Jul 2026US 2026/0207672 A1
- Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells11 Jun 2026US 2026/0158087 A1Mayo Foundation for Medical Education and Research
- Composition and Use Method Therefor14 May 2026US 2026/0131027 A1Nanjing Reju Therapeutics, Co., Ltd.
- Universal t cell-based, cmv-vectored vaccine for influenza2 Apr 2026US 2026/0091102 A1Oregon Health & Science University
- Gene therapy for ceroid lipofuscinoses19 Mar 2026US 2026/0078406 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Production of adeno-associated virus in insect cells138US 6,723,551 B2The United States of America as represented by the Department of Health and Human Services · 2004
- Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features49US 7,723,030 B2Thomas Jefferson University · 2010
- Recombinant human cytomegalovirus containing foreign gene30US 5,273,876 ASyntro Corporation · 1993
- Live recombinant avian vaccine using an avian herpesvirus as vector27US 5,980,906 ARhone Merieux · 1999
- Recombinant cytomegalovirus containing foreign gene and use thereof25US 5,830,745 ASyntro Corporation · 1998